论文部分内容阅读
60例确诊有前列腺增生症的老年患者,口服α-肾上腺素能受体阻滞剂酚苄明后,54例排尿不畅的临床症状有明显改善,6例重度前列腺增生症患者疗效不明显。全组膀胱残余尿治疗后为10.6±6.4ml较治疗前46.6±11.6ml明显减少(P<0.01),而前列腺横径治疗后46.8±0.41cm较治疗前47.3±0,51cm无明显变化(P>0.05)。此药副作用不明显,对轻中度前列腺增生症疗效显著,值得临床应用。
60 cases of elderly patients diagnosed with benign prostatic hyperplasia, oral α-adrenergic receptor antagonist phenoxybenzamine, 54 cases of poor urinary clinical symptoms improved significantly, 6 cases of severe benign prostatic hyperplasia in patients with no significant effect. The residual urinary bladder after treatment was 10.6 ± 6.4ml 46.6 ± 11.6ml significantly lower than before treatment (P <0.01), while the transverse diameter of 46.8 ± 0.41cm after treatment compared with 47.3 ± 0,51cm before treatment no significant change (P > 0.05). The side effects of this drug is not obvious, mild to moderate benign prostatic hyperplasia significant effect, it is worth clinical application.